ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

flotufolastat F 18

Also written as “rhPSMA-7.3 (18F) Injection”, “Flotufolastat F-18 Injection” and “flotufolastat (18F)”.

Its studies are mostly in Prostatic Neoplasms, led by 3 companies.

Drug pageFlotufolastat F 18: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 17, 20247 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Braccoits history only40 open or runningphase 4since Sep 17, 2024Jun 18, 2019none ahead
Sinotau Pharmaceutical Groupits history only20 open or runningphase 1since Aug 4, 2025Aug 4, 2025none ahead
Novartis10 open or runningphase 2since Feb 25, 2025Feb 25, 2025none ahead

Also a collaborator on its studies: Aixial Group and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 25, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT06881823

TargetBeta

FOLH1 →read by rule
“Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells.”study text, by rule · the study

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22
SHR-4394Jiangsu HengRui Medicinephase 22

Studies

The one study Novartis leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06881823Prostatic Neoplasms2WithdrawnMar 31, 20300

How it is read

Names in the registry

  • “rhPSMA-7.3 (18F) Injection”, 3 entries
  • “Flotufolastat F-18 Injection”, 2 entries
  • “flotufolastat (18F)”, 1 entry
  • “Flotufolastat F 18”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.